PPT-Median PFS: 2.6 months (95% CI, 1.7-3.5)

Author : ceila | Published Date : 2023-11-19

Median PFS 14 months 95 CI 1216 Median PFS 12 months 95 CI 047 A B C Cancer Prior to TAS117 n13 TAS117 n13 Subsequent line of treatment n6 Breast cancer 3

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Median PFS: 2.6 months (95% CI, 1.7-3.5)" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Median PFS: 2.6 months (95% CI, 1.7-3.5): Transcript

Median PFS 14 months 95 CI 1216 Median PFS 12 months 95 CI 047 A B C Cancer Prior to TAS117 n13 TAS117 n13 Subsequent line of treatment n6 Breast cancer 3. . Highlights from the Annual Clinical Meeting. Gynecologic Cancer. Sidney A. Scudder, MD. Professor of Medicine. U.C. Davis Cancer Center. Conference Directors:. Helen Chew, MD, FACP. Primo Lara, Jr., MD. Yes . Deborah . Schrag. , MD, MPH. No. John L. Marshall, MD. Maintenance. Why we do it. Optimox. , should we . optimiri. Timing of change. Switch or reduce. What drugs. 5fu or . capecitabine. Bev? . Erlotinib. Agents . for . Indolent . L. ymphoma . and . Mantle Cell Lymphoma. . Stephen Ansell, MD, PhD. Mayo Clinic. Tiacci. et al, Nature . Reviews Cancer 6, 437-. 448, 2006.. Would we expect mantle cell lymphoma and follicular lymphoma to respond to similar agents?. Biliary. Cancers. Abby B. Siegel, MD, MS . Columbia University. Co-Chair, SWOG . Hepatobiliary. Committee. NCI Task Force, . Hepatobiliary. Cancers. Biliary. Anatomy. Adapted from De . Groen. et al, NEJM 1999 Oct 28;341(18):1368-78 . 10/25/2016. Objectives. General principles. Endocrine agents for HR+ pts- . sequencing/combinations. Addition of biological agents. Clinical scenarios. Triple negative subsets. AR positive disease. PARP inhibitors in BRCA mutations. Swiss Group for Clinical Cancer Research (SAKK). 1. Is there Long-Term Benefit . from . Maintenance . Rituximab?. Rationale and aim of maintenance . in haematological malignancies. In patients who have responded to initial induction. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Buparlisib. and . Fulvestrant. in Postmenopausal Women With HR , HER2–, AI-treated, . Locally Advanced or Metastatic Breast Cancer, Who Progressed On or After . mTOR. Inhibitor-based Treatment. Diagnostic work-up. Treatment. The most commonly occurring gynecologic cancer is:. Cervical. Endometrial. Ovarian. Vulvar. The gynecologic cancer with the highest death rate is:. Cervical. Endometrial. Celine Mascaux, MD, . PhD. Multidisciplinary . Oncology & . Therapeutic Innovations . Dept. . Centre de Recherche en Cancérologie de Marseille, . Inserm. . UMR1068. , . CNRS UMR7258 . , Aix-Marseille Université . Lisocabtagene. . Maraleucel. in Relapsed/Refractory (R/R) Large B-Cell Lymphomas . Abramson JS, . Palomba. ML, Gordon LI, . Lunning. M, Wang M, . Arnason. J, Mehta A, . Purev. E, Maloney DG, . Andreadis. of Multiple Myeloma. Kenneth C. Anderson, M.D.. Jerome Lipper Multiple Myeloma Center. Dana-Farber Cancer Institute. Harvard Medical School. . Conflict of Interest: Kenneth C. Anderson, M.D. . Consultancy: . Lung and gastrointestinal cancers. Slide numbers. Study . Author. ESMO ID. 5 – 12. RATIONALE 304: . Tislelizumab + chemotherapy vs chemotherapy alone as 1L treatment for non-squamous NSCLC in patients who are smokers vs non-smokers. Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-Victoria Mateos,. 3. Ola Landgren,. 4. Xavier Leleu,. 5. David Siegel,. 6. Katja Weisel,. 7. Maria Gavriatopoulou,. 8. Albert Oriol,. 9. Neil Rabin,.

Download Document

Here is the link to download the presentation.
"Median PFS: 2.6 months (95% CI, 1.7-3.5)"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.